ArticleSkin pharmacology and physiology2026
Oral Administration of Specific Bioactive Collagen Peptides in the Treatment of Moderate Forms of Atopic Dermatitis: A New Approach.
Article in Skin pharmacology and physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEffective management of atopic dermatitis (AD) remains challenging, as current therapies often rely on topical corticosteroids associated with adverse effects and limited long-term tolerability.
methodsThis double-blind, randomized, placebo-controlled trial investigated the effects of a 12-week oral supplementation with specific bioactive collagen peptides (BCPs, CURADERM®) on clinical symptoms and skin physiology in adults with moderate AD. Participants were randomized to receive either 5 g of BCP or placebo daily.
resultsBCP supplementation led to significantly lower corticosteroid rescue medication use (0.94 ± 1.42 g vs. 5.60 ± 7.82 g; p = 0.045; d = 0.847) and an earlier reduction in pruritus, as shown by improvements in the 5-D Pruritus Scale at week 4 (p = 0.024, d = 1.49). Favourable effects were also observed for key physiological parameters of the skin, including maintenance of physiological pH (4.5-5.5) and improved hydration of lesional areas (p = 0.040, d = 1.44). No treatment-related adverse events occurred.
conclusionTaken together, these findings provide first placebo-controlled evidence that oral BCP supplementation supports skin barrier recovery, stabilizes physiological skin function, and accelerates symptom relief in mild-to-moderate AD. Confirmation of these promising results in larger trials is warranted to validate treatment effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.